{'fraction_non_alphanumeric': 0.014044943820224719, 'fraction_numerical': 0.009831460674157303, 'mean_word_length': 5.3097345132743365, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Patients with multiple myeloma over a large catchment of 2.5 million square kilometres: a Western Australia retrospective survival review

Multiple myeloma is an incurable malignancy of plasma cells. We retrospectively reviewed the survival outcomes of patients with multiple myeloma in Western Australia (WA) public hospitals over a 10‐year period. We did not detect a difference in survival between patients residing in the metropolitan Perth and regional areas, despite a paucity of haematology services in regional WA due to low population density in a large geographic area. Patients with revised international staging system Stage 3 had the poorest survival in our cohort with median survival of 24 months.